Naslov
Systemic therapy of ovarian cancer- the mechanism of action of antineoplastic drugs

Autori
Pavlica, V ; Šeparović, R ; Tečić Vuger, A ; Silovski, T ; Jurić, A

Izvornik
Libri oncologici : Croatian journal of oncology (0300-8142) 43 (2015); 59-65

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
systemic antineoplastic therapy ; ovarian cancer ; chemotherapeutics ; biological drugs ; cell cycle ; cisplatin ; carboplatin ; taxanes ; paclitaxel ; docetaxel ; topotecan ; etoposide ; gemcitabine ; doxorubicin ; bevacizumab ; olaparib

Sažetak
Ovarian cancer treatment consists of surgical options and systemic antineoplastic therapy. Systemic medicamentous therapy, involves a choice of classic chemotherapy and targeted biological treatment. Cytotoxic drugs act nonspecifi cally on tumor cells, damaging also certain proportion of healthy cells in human body. Such drugs act on the basis of impact on the life cycle of cells. Some work throughout the whole cell cycle, phase nonspecifi cally, while others work somewhat more specifi cally for certain phase of cell cycle. Among cell cycle nonspecifi c antineoplastic drugs, a platinum compounds, cisplatin and carboplatin play the main role. A cell cycle phase specifi c activity is seen in a few groups of antineoplastic drugs, among which a signifi cant role in the therapy of ovarian cancer is played by taxanes paclitaxel and docetaxel, camptothecin analogue topotecan, podophyllotoxin etoposide, pyrimidine antagonist gemcitabine and anthracycline doxorubicin. In the treatment of ovarian cancer a signifi cant place is also held by two biological medicines, the so-called “on targeted drugs”, VEGF inhibitor bevacizumab and PARP inhibitor olaparib.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA